ACNU-based chemotherapy for recurrent glioma in the temozolomide era

Journal of Neuro-Oncology

Volumn 92, Issue 1, 2009, Pages 45-48

  Happold, Caroline ^a,b   Roth, Patrick ^a   Wick, Wolfgang ^c   Steinbach, Joachim P ^d   Linnebank, Michael ^b   Weller, Michael ^b   Eisele, Günter ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Chemotherapy; Glioma; Nimustine; Recurrence; Temozolomide

Indexed keywords

CILENGITIDE; CYTARABINE; DEXAMETHASONE; INDOMETACIN; NIMUSTINE; TEMOZOLOMIDE; TENIPOSIDE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GLIOBLASTOMA; HERPES ZOSTER; HUMAN; LEUKOENCEPHALOPATHY; LEUKOPENIA; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGRESSION FREE SURVIVAL; RECURRENT DISEASE; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING; WOUND HEALING IMPAIRMENT;

EID: 59349085941     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-008-9728-9     Document Type: Article

References (19)

1. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996. doi: 10.1056/NEJMoa043330
2. Glioma Meta-analysis Trialist (GMT) Group (2002) Chemotherapy for high-grade glioma. Cochrane Database Syst Rev (Online):CD003913
3. Medical Research Council Brain Tumor Working Party (2001) Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: A Medical Research Council trial. J Clin Oncol 19:509-518
4. Weller M, Muller B, Koch R et al (2003) Neuro-oncology working group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J Clin Oncol 21:3276-3284. doi: 10.1200/JCO.2003.03.509
5. Kato H, Fujimura M, Kumabe T et al (2004) PTEN gene mutation and high MIB-1 labeling index may contribute to dissemination in patients with glioblastoma. J Clin Neurosci 11:37-41. doi: 10.1016/j.jocn.2002.09.001
6. Tanaka M, Shibui S, Nomura K et al (2001) Radiotherapy combined with nimustine hydrochloride and etoposide for malignant gliomas: Results of a pilot study. Jpn J Clin Oncol 31:246-250. doi: 10.1093/jjco/hye059
7. Wolff JE, Berrak S, Koontz Webb SE et al (2008) Nitrosourea efficacy in high-grade glioma: A survival gain analysis summarizing 504 cohorts with 24193 patients. J Neurooncol 88:57-63. doi: 10.1007/s11060-008-9533-5
8. Brandes AA, Tosoni A, Amista P et al (2004) How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology 63:1281-1284
9. Brandes AA, Turazzi S, Basso U et al (2002) A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme. Neurology 58:1759-1764
10. Kappelle AC, Postma TJ, Taphoorn MJ et al (2001) PCV chemotherapy for recurrent glioblastoma multiforme. Neurology 56:118-120
11. Schmidt F, Fischer J, Herrlinger U et al (2006) PCV chemotherapy for recurrent glioblastoma. Neurology 66:587-589. doi: 10.1212/ 01.wnl.0000197792.73656.c2
12. Macdonald DR, Cascino TL, Schold SC Jr et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280
13. Carson KA, Grossman SA, Fisher JD et al (2007) Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol 25:2601-2606. doi: 10.1200/JCO.2006.08.1661
14. Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572-2578
15. Lamborn KR, Yung WK, Chang SM et al (2008) Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas. Neuro oncol 10:162-170. doi: 10.1215/15228517-2007-062
16. Yung WK, Albright RE, Olson J et al (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588-593. doi: 10.1054/bjoc.2000.1316
17. Wick A, Felsberg J, Steinbach JP et al (2007) Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25:3357-3361. doi: 10.1200/ JCO.2007.10.7722
18. Vredenburgh JJ, Desjardins A, Herndon JEII et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722-4729. doi: 10.1200/JCO.2007.12.2440
19. Vredenburgh JJ, Desjardins A, Herndon JEII et al (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253-1259. doi: 10.1158/1078-0432.CCR-06-2309